1. Inicio
  2. Investigación
  3. Grupos de investigación
  4. Patología Molecular del Cáncer

Patología Molecular del Cáncer

Buscador de publicaciones

Sólo se han incluido artículos originales, editoriales y revisiones.

  • García MJ, Saucedo-Cuevas LP, Muñoz-Repeto I, Fernández V, Robles MJ, Domingo S, Palacios J, Aracil M, Nieto A, Tercero JC, Benítez J.

    Analysis of DNA Repair-Related Genes in Breast Cancer Reveals CUL4A Ubiquitin Ligase as a Novel Biomarker of Trabectedin Response

    MOLECULAR CANCER THERAPEUTICS . 12(4): 530-541. Nº de citas: 16

    [doi:10.1158/1535-7163.MCT-12-0768]

  • Romero-Pérez L, Castilla MÁ, López-García MÁ, Díaz-Martín J, Biscuola M, Ramiro-Fuentes S, Oliva E, Matias-Guiu X, Prat J, Cano A, Moreno-Bueno G, Palacios J.

    Molecular events in endometrial carcinosarcomas and the role of high mobility group AT-hook 2 in endometrial carcinogenesis

    HUMAN PATHOLOGY . 44(2): 244-254. Nº de citas: 26

    [doi:10.1016/j.humpath.2012.05.013]

  • Yeramian A, Moreno-Bueno G, Dolcet X, Catasus L, Abal M, Colas E, Reventos J, Palacios J, Prat J, Matias-Guiu X.

    Endometrial carcinoma: molecular alterations involved in tumor development and progression

    Oncogene . 32(4): 403-413. Nº de citas: 120

    [doi:10.1038/onc.2012.76]

  • Muñoz-Repeto I, García MJ, Kamieniak M, Ramón Y Cajal T, Domingo S, Cazorla A, García Donas J, Hernando Polo S, García Sagredo JM, Hernández E, Lacambra C, Saez R, Robles L, Borrego S, Prat J, Palacios J, Benítez J.

    Phenotypic characterization of hereditary epithelial ovarian cancer based on a tissue microarray study

    HISTOLOGY AND HISTOPATHOLOGY . 28(1): 133-144. Nº de citas: 3

  • Castilla MÁ, Díaz-Martín J, Sarrió D, Romero-Pérez L, López-García MÁ, Vieites B, Biscuola M, Ramiro-Fuentes S, Isacke CM, Palacios J.

    MicroRNA-200 Family Modulation in Distinct Breast Cancer Phenotypes

    Plos One . 7(10): . Nº de citas: 84

    [doi:10.1371/journal.pone.0047709]

  • Bastien RR, Rodríguez-Lescure Á, Ebbert MT, Prat A, Munárriz B, Rowe L, Miller P, Ruiz-Borrego M, Anderson D, Lyons B, Álvarez I, Dowell T, Wall D, Seguí MÁ, Barley L, Boucher KM, Alba E, Pappas L, Davis CA, Aranda I, Fauron C, Stijleman IJ, Palacios J, Antón A, Carrasco E, Caballero R, Ellis MJ, Nielsen TO, Perou CM, Astill M, Bernard PS, Martín M.

    PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers

    BMC MEDICAL GENOMICS . 5: 44-44. Nº de citas: 196

    [doi:10.1186/1755-8794-5-44]

  • Colas E, Pedrola N, Devis L, Ertekin T, Campoy I, Martínez E, Llauradó M, Rigau M, Olivan M, Garcia M, Cabrera S, Gil-Moreno A, Xercavins J, Castellvi J, Garcia A, Ramon y Cajal S, Moreno-Bueno G, Dolcet X, Alameda F, Palacios J, Prat J, Doll A, Matias-Guiu X, Abal M, Reventos J.

    The EMT signaling pathways in endometrial carcinoma

    CLINICAL & TRANSLATIONAL ONCOLOGY . 14(10): 715-720. Nº de citas: 77

    [doi:10.1007/s12094-012-0866-3]

  • Leandro-García LJ, Leskelä S, Inglada-Pérez L, Landa I, de Cubas AA, Maliszewska A, Comino-Méndez I, Letón R, Gómez-Graña Á, Torres R, Ramírez JC, Álvarez S, Rivera J, Martínez C, Lozano ML, Cascón A, Robledo M, Rodríguez-Antona C.

    Hematologic beta-Tubulin VI Isoform Exhibits Genetic Variability That Influences Paclitaxel Toxicity

    CANCER RESEARCH . 72(18): 4744-4752. Nº de citas: 22

    [doi:10.1158/0008-5472.CAN-11-2861]

  • Leandro-García LJ, Leskelä S, Jara C, Gréen H, Avall-Lundqvist E, Wheeler HE, Dolan ME, Inglada-Perez L, Maliszewska A, de Cubas AA, Comino-Méndez I, Mancikova V, Cascón A, Robledo M, Rodríguez-Antona C.

    Regulatory Polymorphisms in beta-Tubulin IIa Are Associated with Paclitaxel-Induced Peripheral Neuropathy

    CLINICAL CANCER RESEARCH . 18(16): 4441-4448. Nº de citas: 53

    [doi:10.1158/1078-0432.CCR-12-1221]

  • Llauradó M, Ruiz A, Majem B, Ertekin T, Colás E, Pedrola N, Devis L, Rigau M, Sequeiros T, Montes M, Garcia M, Cabrera S, Gil-Moreno A, Xercavins J, Castellví J, Garcia A, Ramón y Cajal S, Moreno G, Alameda F, Vázquez-Levin M, Palacios J, Prat J, Doll A, Matías-Guiu X, Abal M, Reventós J.

    Molecular bases of endometrial cancer: New roles for new actors in the diagnosis and the therapy of the disease

    MOLECULAR AND CELLULAR ENDOCRINOLOGY . 358(2, SI): 244-255. Nº de citas: 40

    [doi:10.1016/j.mce.2011.10.003]

  • Sánchez-Rovira P, Antón A, Barnadas A, Velasco A, Lomas M, Rodríguez-Pinilla M, Ramírez JL, Ramírez C, Ríos MJ, Castellá E, García-Andrade C, San Antonio B, Carrasco E, Palacios JL.

    Classical markers like ER and ki-67, but also survivin and pERK, could be involved in the pathological response to gemcitabine, adriamycin and paclitaxel (GAT) in locally advanced breast cancer patients: results from the GEICAM/2002-01 phase II study

    CLINICAL & TRANSLATIONAL ONCOLOGY . 14(6): 430-436. Nº de citas: 10

    [doi:10.1007/s12094-012-0820-4]

  • Hernandez L, Wilkerson PM, Lambros MB, Campion-Flora A, Rodrigues DN, Gauthier A, Cabral C, Pawar V, Mackay A, A'hern R, Marchiò C, Palacios J, Natrajan R, Weigelt B, Reis-Filho JS.

    Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection

    JOURNAL OF PATHOLOGY . 227(1): 42-52. Nº de citas: 111

    [doi:10.1002/path.3990]

  • Durán-Prado M, Gahete MD, Hergueta-Redondo M, Martínez-Fuentes AJ, Córdoba-Chacón J, Palacios J, Gracia-Navarro F, Moreno-Bueno G, Malagón MM, Luque RM, Castaño JP.

    The new truncated somatostatin receptor variant sst5TMD4 is associated to poor prognosis in breast cancer and increases malignancy in MCF-7 cells

    Oncogene . 31(16): 2049-2061. Nº de citas: 54

    [doi:10.1038/onc.2011.389]

  • Albanell J, González A, Ruiz-Borrego M, Alba E, García-Saenz JA, Corominas JM, Burgues O, Furio V, Rojo A, Palacios J, Bermejo B, Martínez-García M, Limon ML, Muñoz AS, Martín M, Tusquets I, Rojo F, Colomer R, Faull I, Lluch A.

    Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER plus ) node-negative breast cancer

    ANNALS OF ONCOLOGY . 23(3): 625-631. Nº de citas: 93

    [doi:10.1093/annonc/mdr278]

  • Santacana M, Yeramian A, Velasco A, Bergada L, Gatius S, García V, Azueta A, Palacios J, Dolcet X, Oliva E, Matias-Guiu X.

    Immunohistochemical features of post-radiation vaginal recurrences of endometrioid carcinomas of the endometrium: role for proteins involved in resistance to apoptosis and hypoxia

    Histopathology . 60(3): 460-471. Nº de citas: 12

    [doi:10.1111/j.1365-2559.2011.04106.x]

  • Moch H, Blank PR, Dietel M, Elmberger G, Kerr KM, Palacios J, Penault-Llorca F, Rossi G, Szucs TD.

    Personalized cancer medicine and the future of pathology

    VIRCHOWS ARCHIV . 460(1): 3-8. Nº de citas: 27

    [doi:10.1007/s00428-011-1179-6]

  • Natrajan R, Mackay A, Wilkerson PM, Lambros MB, Wetterskog D, Arnedos M, Shiu KK, Geyer FC, Langerød A, Kreike B, Reyal F, Horlings HM, van de Vijver MJ, Palacios J, Weigelt B, Reis-Filho JS.

    Functional characterization of the 19q12 amplicon in grade III breast cancers

    BREAST CANCER RESEARCH . 14(2): . Nº de citas: 51

    [doi:10.1186/bcr3154]

  • Wetterskog D, Lopez-Garcia MA, Lambros MB, A'Hern R, Geyer FC, Milanezi F, Cabral MC, Natrajan R, Gauthier A, Shiu KK, Orr N, Shousha S, Gatalica Z, Mackay A, Palacios J, Reis-Filho JS, Weigelt B.

    Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers

    JOURNAL OF PATHOLOGY . 226(1): 84-96. Nº de citas: 105

    [doi:10.1002/path.2974]